This test measures pregnanediol, a metabolite of progesterone. It is used in the evaluation and decision making in women who are having difficulty becoming pregnant or maintaining a pregnancy. It is also used to monitor “high-risk” pregnancies.
Urinary pregnanediol is measured to evaluate progesterone production by the ovaries and placenta. The main effect of progesterone is on the endometrium. It initiates the secretory phase of the endometrium in anticipation of implantation of a fertilized ovum.
Usually, progesterone is secreted by the ovarian corpus luteum after ovulation. Both serum progesterone levels and urine concentration of progesterone metabolites (pregnanediol and others) are significantly increased during the second half of an ovulatory cycle.
Pregnanediol is the most easily measured metabolite of progesterone. Because pregnanediol levels rise rapidly after ovulation, this study is useful in checking whether ovulation has occurred and, if so, exactly when. During pregnancy, pregnanediol levels normally rise because of placental production of progesterone. Repeated testing can be used to monitor the status of the placenta in women who have difficulty becoming pregnant or maintaining a pregnancy. Repeated testing can also be used to monitor the status of the placenta in high-risk pregnancy. Hormone testing for urinary pregnanediol are primarily used to monitor progesterone supplementation in patients with an inadequate luteal phase to maintain an early pregnancy. Urinary assays may be supplemented by plasma testing, which are quicker and more accurate.
Various normal ranges*:
*the Luteal Range is the premenopausal range. When patients are taking oral progesterone this range for progesterone metabolites is not luteal and reflects the higher levels expected when patients take oral progesterone. This test is intended to be taken in the luteal phase of the menstrual cycle (days 19-22 of a 28 day cycle) for premenopausal women.
- Lobo RA. Reproductive endocrinology: neuroendocrinology, gonadotropins, sex steroids, prostaglandins, ovulation, menstruation, hormone assay. In: Katz VL, Lentz GM, Lobo RA, Gershenson DM, eds. Comprehensive Gynecology. 5th ed. Philadelphia, Pa: Mosby Elsevier; 2007:chap 4.
- Lehmann HP, Henry JB. SI units. In: McPherson RA, Pincus MR, eds. Henry’s Clinical Diagnosis and Management by Laboratory Methods. 21st ed. Philadelphia, Pa: Saunders Elsevier; 2006:appendix 5.
Low or low-normal levels of pregnanediol signal less than optimal progesterone. This commonly results in an increase in symptoms occurring in the luteal phase. In the perimenopausal years, progesterone levels tend to fall faster than estrogens, resulting in a relative estrogen dominance. Botanicals or supplemental progesterone can be useful for managing symptoms. Low levels are commonly associated with sleep disturbances, anxiety, stress, and edema.
In postmenopausal women the level of pregnanediol is expected to be much lower than in premenopausal women with optimal luteal ovarian function.
Possible causes of low levels:
- Progesterone is made by the placenta during pregnancy. Pregnanediol is a metabolite of progesterone, which is decreased when placental viability is threatened.
- Ovarian neoplasm: Ovarian epithelial cancers can destroy functional ovarian tissue. Progesterone levels may decrease.
- Amenorrhea, Ovarian hypofunction: Without ovulation, a corpus luteum will not develop. Progesterone will not be secreted, and progesterone and pregnanediol levels will be lower than expected.
- Ovulation: Ovulation occurs with development of a corpus luteum, which makes progesterone. Pregnanediol is a metabolite of progesterone.
- Pregnancy: A healthy placenta produces progesterone. Pregnanediol is a metabolite of progesterone.
- Molar pregnancy: Hydatidiform mole can produce progesterone, although at lower levels than during pregnancy.
- Luteal cysts of ovary: The corpus luteum produces progesterone in the nonpregnant woman and in the early stages of pregnancy. Cysts can also produce progesterone for prolonged periods of time. Pregnanediol is a metabolite of progesterone.
- Arrhenoblastoma of ovary: This tumor can secrete sex hormones or their metabolites (usually testosterone). 17-Hydroxyprogesterone is a precursor of sex hormones. Pregnanediol is a metabolite of progesterone.
- Hyperadrenocorticism, Adrenocortical hyperplasia: Adrenal cortical hormones are secreted at increased rates. 17-Hydroxyprogesterone is a precursor of these cortical hormones. Pregnanediol is a metabolite of progesterone.
- Choriocarcinoma of ovary: This tumor produces progesterone.
Get Started With Our Personal Plan
Are You a Health Professional?
Get started with our professional plan
Welcome to Healthmatters Pro.
Save time on interpreting lab results with the largest database of biomarkers online. In-depth research on any test at your fingertips, all stored and tracked in one place. Learn more
for health professionals
$45 per month